Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea

Sun Young Park, Euna Han, Jini Kim, Eui Kyung Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study analyzed factors contributing to increases in the actual sales volumes relative to forecasted volumes of drugs under price–volume agreement (PVA) policy in South Korea. Sales volumes of newly listed drugs on the national formulary are monitored under PVA policy. When actual sales volume exceeds the pre-agreed forecasted volume by 30% or more, the drug is subject to price-reduction. Logistic regression assessed the factors related to whether drugs were the PVA price-reduction drugs. A generalized linear model with gamma distribution and log-link assessed the factors influencing the increase in actual volumes compared to forecasted volume in the PVA price-reduction drugs. Of 186 PVA monitored drugs, 34.9% were price-reduction drugs. Drugs marketed by pharmaceutical companies with previous-occupation in the therapeutic markets were more likely to be PVA price-reduction drugs than drugs marketed by firms with no previous-occupation. Drugs of multinational pharmaceutical companies were more likely to be PVA price-reduction drugs than those of domestic companies. Having more alternative existing drugs was significantly associated with higher odds of being PVA price-reduction drugs. Among the PVA price-reduction drugs, the increasing rate of actual volume compared to forecasted volume was significantly higher in drugs with clinical usefulness. By focusing the negotiation efforts on those target drugs, PVA policy can be administered more efficiently with the improved predictability of the drug sales volumes.

Original languageEnglish
Pages (from-to)867-874
Number of pages8
JournalHealth Policy
Volume120
Issue number8
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Republic of Korea
Pharmaceutical Preparations
Occupations

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

@article{8f08590786b44a0f8cc9e0ec7bea9b9d,
title = "Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea",
abstract = "This study analyzed factors contributing to increases in the actual sales volumes relative to forecasted volumes of drugs under price–volume agreement (PVA) policy in South Korea. Sales volumes of newly listed drugs on the national formulary are monitored under PVA policy. When actual sales volume exceeds the pre-agreed forecasted volume by 30{\%} or more, the drug is subject to price-reduction. Logistic regression assessed the factors related to whether drugs were the PVA price-reduction drugs. A generalized linear model with gamma distribution and log-link assessed the factors influencing the increase in actual volumes compared to forecasted volume in the PVA price-reduction drugs. Of 186 PVA monitored drugs, 34.9{\%} were price-reduction drugs. Drugs marketed by pharmaceutical companies with previous-occupation in the therapeutic markets were more likely to be PVA price-reduction drugs than drugs marketed by firms with no previous-occupation. Drugs of multinational pharmaceutical companies were more likely to be PVA price-reduction drugs than those of domestic companies. Having more alternative existing drugs was significantly associated with higher odds of being PVA price-reduction drugs. Among the PVA price-reduction drugs, the increasing rate of actual volume compared to forecasted volume was significantly higher in drugs with clinical usefulness. By focusing the negotiation efforts on those target drugs, PVA policy can be administered more efficiently with the improved predictability of the drug sales volumes.",
author = "Park, {Sun Young} and Euna Han and Jini Kim and Lee, {Eui Kyung}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.healthpol.2016.06.004",
language = "English",
volume = "120",
pages = "867--874",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "8",

}

Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea. / Park, Sun Young; Han, Euna; Kim, Jini; Lee, Eui Kyung.

In: Health Policy, Vol. 120, No. 8, 01.08.2016, p. 867-874.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea

AU - Park, Sun Young

AU - Han, Euna

AU - Kim, Jini

AU - Lee, Eui Kyung

PY - 2016/8/1

Y1 - 2016/8/1

N2 - This study analyzed factors contributing to increases in the actual sales volumes relative to forecasted volumes of drugs under price–volume agreement (PVA) policy in South Korea. Sales volumes of newly listed drugs on the national formulary are monitored under PVA policy. When actual sales volume exceeds the pre-agreed forecasted volume by 30% or more, the drug is subject to price-reduction. Logistic regression assessed the factors related to whether drugs were the PVA price-reduction drugs. A generalized linear model with gamma distribution and log-link assessed the factors influencing the increase in actual volumes compared to forecasted volume in the PVA price-reduction drugs. Of 186 PVA monitored drugs, 34.9% were price-reduction drugs. Drugs marketed by pharmaceutical companies with previous-occupation in the therapeutic markets were more likely to be PVA price-reduction drugs than drugs marketed by firms with no previous-occupation. Drugs of multinational pharmaceutical companies were more likely to be PVA price-reduction drugs than those of domestic companies. Having more alternative existing drugs was significantly associated with higher odds of being PVA price-reduction drugs. Among the PVA price-reduction drugs, the increasing rate of actual volume compared to forecasted volume was significantly higher in drugs with clinical usefulness. By focusing the negotiation efforts on those target drugs, PVA policy can be administered more efficiently with the improved predictability of the drug sales volumes.

AB - This study analyzed factors contributing to increases in the actual sales volumes relative to forecasted volumes of drugs under price–volume agreement (PVA) policy in South Korea. Sales volumes of newly listed drugs on the national formulary are monitored under PVA policy. When actual sales volume exceeds the pre-agreed forecasted volume by 30% or more, the drug is subject to price-reduction. Logistic regression assessed the factors related to whether drugs were the PVA price-reduction drugs. A generalized linear model with gamma distribution and log-link assessed the factors influencing the increase in actual volumes compared to forecasted volume in the PVA price-reduction drugs. Of 186 PVA monitored drugs, 34.9% were price-reduction drugs. Drugs marketed by pharmaceutical companies with previous-occupation in the therapeutic markets were more likely to be PVA price-reduction drugs than drugs marketed by firms with no previous-occupation. Drugs of multinational pharmaceutical companies were more likely to be PVA price-reduction drugs than those of domestic companies. Having more alternative existing drugs was significantly associated with higher odds of being PVA price-reduction drugs. Among the PVA price-reduction drugs, the increasing rate of actual volume compared to forecasted volume was significantly higher in drugs with clinical usefulness. By focusing the negotiation efforts on those target drugs, PVA policy can be administered more efficiently with the improved predictability of the drug sales volumes.

UR - http://www.scopus.com/inward/record.url?scp=84995685570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995685570&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2016.06.004

DO - 10.1016/j.healthpol.2016.06.004

M3 - Article

C2 - 27346072

AN - SCOPUS:84995685570

VL - 120

SP - 867

EP - 874

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 8

ER -